Author's response to reviews

Title: 5-alpha Reductase Inhibitors and Prostate Cancer Prevention: where do we turn now?

Authors:

Robert J Hamilton (roberthamilton@sympatico.ca)
Stephen J Freedland (steve.freedland@duke.edu)

Version: 4 Date: 22 June 2011

Author's response to reviews: see over
June 22, 2011

Dr. Robin Cassady-Cain,
Reviews Editor, BMC Medicine
BioMed Central
Floor 6, 236 Gray's Inn Road
London, WC1X 8HL

Dr. Cassady-Cain,

This letter accompanies the electronic re-submission of our article entitled, “5-alpha Reductase Inhibitors and Prostate Cancer Prevention: where do we turn now?” Please re-consider our submission for publication as an invited commentary in *BMC Medicine*.

We sincerely appreciate the comments of the reviewers and your own and have responded to the comments with appropriate changes to the manuscript. Below is the detailed response to each reviewer’s comments.

**Review #1:**

1) Minor Essential Revisions
   - A table comparing the two trials would be helpful

2) Discretionary Revisions
   - I recommend to at least cite some of the cost effectiveness articles published to also address that thorny issue
   - I recommend to provide actual numbers for the high risk cancers since the reader should understand the magnitude of the GS 8-10 cancer issue

**REPLY:** We thank the reviewer for their comments. We have added a table comparing the two trials; added a paragraph pertaining to the cost-effectiveness of 5-ARIs; and added the numbers of cancers with Gleason ≥8.

**Reviewer #2:**

1) The abstract presented by Neil Fleshner at the 2011 ASCO could have been included and discussed. The reviewer acknowledges that it is not a peer-reviewed published paper but it constitutes an important piece of information. The use of 5ARIs in men with low volume low grade PCa managed by AS is certainly worth mentioning and discussing.

**REPLY:** We thank the reviewer for their comments. We have added a paragraph about the potential role of 5-ARIs as secondary prevention agents, including the reference mentioned.

We believe the manuscript has improved and is suitable for publication. Thank you again for considering our manuscript.

Sincerely,

Stephen Freedland
Associate Professor of Urology and Pathology
Director of Outcomes and Translational Research, Urological Surgery
Box 2626, Duke University Medical Center
Durham, NC 27710
phone 919-668-5946
fax 919-668-7093